Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Clin Chem Lab Med. 2024 Jan 23. doi: 10.1515/cclm-2023-1434. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD), a primary cause of dementia globally, is traditionally diagnosed via cerebrospinal fluid (CSF) measures and positron emission tomography (PET). The invasiveness, cost, and limited accessibility of these methods have led to exploring blood-based biomarkers as a promising alternative for AD diagnosis and monitoring. Recent advancements in sensitive immunoassays have identified potential blood-based biomarkers, such as Aβ42/Aβ40 ratios and phosphorylated tau (p-tau) species. This paper briefly evaluates the clinical utility and reliability of these biomarkers across various AD stages, highlighting challenges like refining plasma Aβ42/Aβ40 assays and enhancing the precision of p-tau, particularly p-tau181, p-tau217, and p-tau231. The discussion also covers other plasma biomarkers like neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and synaptic biomarkers, assessing their significance in AD diagnostics. The need for ongoing research and development of robust assays to match the performance of CSF and PET biomarkers is underscored. In summary, blood-based biomarkers are increasingly crucial in AD diagnosis, follow-up, prognostication, treatment response evaluation, and population screening, particularly in primary care settings. These developments are set to revolutionize AD diagnostics, offering earlier and more accessible detection and management options.
PMID:38253262 | DOI:10.1515/cclm-2023-1434
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3 Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults Physical activity may a probably protective factor for postoperative delirium: the PNDABLE study Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS) Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies Plasma biomarkers increase diagnostic confidence in patients with Alzheimer's disease or frontotemporal lobar degeneration A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study CO2 cerebrovascular reactivity measured with CBF-MRI in older individuals: Association with cognition, physical function, amyloid, and tau proteins Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly Oculomics: A Crusade Against the Four Horsemen of Chronic Disease Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline Associations of CSF BACE1 with amyloid pathology, neurodegeneration, and cognition in Alzheimer's disease Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease Towards cascading genetic risk in Alzheimer's disease Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians Adaptive immune changes associate with clinical progression of Alzheimer's disease Biomarkers - Part 1 Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort Choriocapillaris reduction accurately discriminates against early-onset Alzheimer's disease Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis Alzheimer-Type Cerebral Amyloidosis in the Context of HIV Infection: Implications for a Proposed New Treatment Approach Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases Biomarkers of Bipolar Disorder in Late Life: An Evidence-Based Systematic Review The association of blood biomarkers with cerebral white matter and myelin content in bipolar disorder: a systematic review Proteomic studies in VWA1-related neuromyopathy allowed new pathophysiological insights and the definition of blood biomarkers APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis Kinetic modeling of the monoamine oxidase-B radioligand [(18)F]SMBT-1 in human brain with positron emission tomography Neurofilament light chain is elevated in patients with newly diagnosed idiopathic intracranial hypertension: A prospective study COVID-19 vaccination may prevent postoperative delirium in elderly patients undergoing elective non-cardiac surgery: The PNDRFAP and PNDABLE studies
Evidence Blueprint
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
CRISPR-Powered Aptasensor for Diagnostics of Alzheimer's Disease Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic Biomarkers in Alzheimer's disease Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology Use of modern classification systems for complex diagnostics of Alzheimer's disease Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias Association between Modifiable Risk Factors and Levels of Blood-Based Biomarkers of Alzheimer's and Related Dementias in the Look AHEAD Cohort Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease Biomarkers of Alzheimer's disease and cerebrovascular disease in relation to depressive symptomatology in individuals with subjective cognitive decline CSF metabolites associated with biomarkers of Alzheimer's disease pathology Association of CSF biomarkers with MRI brain changes in Alzheimer's disease CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p-tau217 Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study Potential Utility of Plasma Biomarker Panels in Differential Diagnosis of Alzheimer's Disease High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease Neuropsychiatric Symptoms and Alzheimer Disease Biomarkers Independently Predict Progression to Incident Cognitive Impairment Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms Biomarkers associated with the pathogenesis of Alzheimer's disease Diagnostic utility of cerebrospinal fluid biomarkers in patients with rapidly progressive dementia